Company Summary:
Atavistik Bio is a privately-held clinical stage biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs. Our proprietary AMPS™ platform allows us to rapidly unlock functional cryptic pockets across a broad range of target classes to accelerate the development of groundbreaking medicines. We have rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery.
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management.
Position Summary:
We are seeking a Senior Scientist, DMPK, to join our R&D group and work with an enthusiastic team of highly skilled scientists in a fast-pace environment. Reporting to the Senior Director, DMPK, this individual will be responsible for the design, execution, reviewing and interpreting the non-clinical DMPK data. This work supports the progression of therapies from discovery through first in human and proof of concept clinical studies. This is a great opportunity to contribute to an efficient DMPK function while being part of an exciting early-stage company.
Key Responsibilities:
- Representative DMPK as a member of preclinical teams.
- Function as a key member of Atavistik Bio’s scientific team, providing scientific expertise, strategic planning, and goal-oriented execution.
- Effectively communicate scientific planning, progress, results and challenges to R&D teams, and external audiences.
- Propose ADME/PK, biodistribution and PK-PD approaches at team discussions of high impact on project progression.
- Manage consultants and vendors to support DMPK studies.
- Partner with the discovery group to optimize preclinical models and inform on first in human clinical dosing strategies.
- Review preclinical study reports, in conjunction with Pharmacokinetics/DMPK and prepare regulatory submission documentation.
- Lead and oversee in-vitro ADME/DMPK assays (metabolic stability, CYP, PPB, permeability, solubility).
- Interpret DMPK data to guide structure–property relationships and compound selection.
- Support and interpret in-vivo PK and bioanalytical data (LC-MS/MS) and work collaboratively with the pharmacology leads to understand the PK/PD/Efficacy relationships.
- Develop DMPK strategies for hit-to-lead and lead optimization programs and inform on first in human clinical dosing strategies.
- Interface with CROs and external partners when needed.
- Collaborate cross functionally with all relevant areas to support strategic objectives.
Required Qualifications:
- PhD., Pharm. D. or equivalent training in pharmacokinetics, pharmaceutical sciences, or related disciplines.
- 5+ years of experience in bio/pharmaceutical industry, combined with drug development.
- Excellent communication and collaborative skills to work on multiple project teams including chemists, biologists and platform scientists.
- Highly organized, self-motivated with a desire to succeed in a fast-paced organization.
- Solid understanding of drug metabolism, bioanalysis, pharmacokinetics, preclinical pharmacology, and PK/PD modeling.
- Expertise in SAR analysis and IVIVC.
- Expertise managing CROs, GLP and other regulated activities.
- Ability to operate objectively and independently as a leader and as a member of a team.
- Experience with regulatory submissions for small molecules with a focus on preclinical is a plus.
- Experience in nonclinical toxicology is a plus.
Atavistik Bio Cambridge, Massachusetts, USA Office
Cambridge, MA, United States, 12139
Similar Jobs
What you need to know about the Boston Tech Scene
Key Facts About Boston Tech
- Number of Tech Workers: 269,000; 9.4% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Thermo Fisher Scientific, Toast, Klaviyo, HubSpot, DraftKings
- Key Industries: Artificial intelligence, biotechnology, robotics, software, aerospace
- Funding Landscape: $15.7 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Summit Partners, Volition Capital, Bain Capital Ventures, MassVentures, Highland Capital Partners
- Research Centers and Universities: MIT, Harvard University, Boston College, Tufts University, Boston University, Northeastern University, Smithsonian Astrophysical Observatory, National Bureau of Economic Research, Broad Institute, Lowell Center for Space Science & Technology, National Emerging Infectious Diseases Laboratories


